AHA 2025 Resource Hub  – 

Welcome to our resource hub for AHA 2025. This is a one-stop-shop for all your AHA needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

Diabetes Therapy Highlights

  1. GLP-1 RAs are associated with better all-cause mortality and CV outcomes in people with hypertrophic cardiomyopathy
  2. APOC3 and HDL particle composition as drivers of CVD risk in T1D
  3. RAGE/DIAPH1 as a novel therapeutic target for diabetic complications
  4. Prespecified analysis of SURPASS-CVOT: Baseline SGLT-2 inhibitor use or initiation does not affect CV benefits of tirzepatide or dulaglutide
  5. Combination therapy with GLP-1 RAs and SGLT-2 inhibitors in T2D
  6. Triple GLP-1/glucagon/FGF-21 RA demonstrates significant metabolic benefits and liver fat reduction in a phase 2 trial
  7. Pre-specified SURPASS-CVOT: Tirzepatide reduces risk of coronary revascularization and hospitalization due to unstable angina in people with T2D when compared with dulaglutide
  8. Tirzepatide and semaglutide demonstrate cardiovascular benefits in people with T2D in real-world settings
  9. Dual SGLT-1/SGLT-2 inhibitor sotagliflozin shows consistent ~40% MACE reduction across pooled phase 3 T2D trials, reinforcing SCORED findings
  10. Pre-specified of FINE-HEART finds finerenone reduces sudden death across cardiovascular-kidney-metabolic syndrome
  11. Cardioprotective mechanisms behind GLP-1 RAs are independent of A1c reduction or weight loss
  12. Pre-specified analysis of SURPASS-CVOT finds that tirzepatide is superior to dulaglutide for the composite of all-cause death and HF events
  13. GLP-1 RAs as more than a weight loss therapy: Dr. Rodica Busui on the SOUL trial and the new era of precision medicine
  14. Reconsidering the role of incretin therapies: Shifting the focus toward peripheral artery disease
  15. Heart and liver protection from GLP-1 RAs are independent of weight loss
  16. Real-world and post-trial evidence across semaglutide and tirzepatide: Implications for cardiovascular risk
  17. SELECT post-hoc analysis: Semaglutide demonstrated benefits regardless of baseline frailty status
  18. Early GLP-1 RA use and benefits across diverse older and high-risk populations
  19. Finerenone in the liver: Post-hoc analysis of FINEARTS-HF trial

Diabetes Big Picture Highlights

  1. Landmark VESALIUS-CV trial supports early and intensive lipid management in people with high CV risk or atherosclerosis, including PWD
  2. The “pillars” of DKD: Best clinical practices for minimizing cardiovascular risk in people with DKD
  3. Dr. Richard Pratley on the mechanistic link between diabetic kidney disease and CVD: Metabolic aging and environmental factors
  4. Bonus Highlight! Administrator Dr. Mehmet Oz highlights CMS’s efforts to “Make America Healthy Again”
  5. Drs. Deepak L. Bhatt, Christie Ballantyne, and Erin Michos on cardiometabolic interventions on atherosclerosis
  6. Cardiovascular‑kidney‑liver-metabolic syndrome: Prevention, screening, and management strategies led by risk-stratification
  7. Redefining obesity: Moving beyond BMI toward mechanisms, early markers, and the lived patient experience
  8. Closing the CKM care gap through equitable access and interdisciplinary care models
  9. AHA 2025’s exhibit hall buzzes with free ASCVD testing, puppies, VR simulations, and more!
  10. Prof. Stephen Nicholls on the SURPASS-CVOT trial as a turning point for CVOT trial design
  11. Presence of diabetes significantly amplifies cardiovascular risk in individuals with elevated Lp(a)

Day-by-Day Highlights

  1. AHA Day #1 Highlights
  2. AHA Day #2 Highlights
  3. AHA Day #3 Highlights
  4. AHA Day #4 Highlights

Previous AHA Coverage on CCKB

AHA 2025 Resource Hub -
Top